Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
May 21, 2024 01:30 ET
|
Sanofi - Aventis Groupe
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build...
Nextensa : RESULTS ON Q1 2024
May 21, 2024 01:30 ET
|
Nextensa NV
REGULATED INFORMATION Brussels, 21 May 2024, 07h30 NEXTENSA: RESULTS ON Q1 2024 HIGHLIGHTS INVESTMENT PROPERTIES • Despite some property sales in 2023 and 2024, rental income...
BGHL (GBP): NAV(s)
May 21, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
BGHL (EUR): NAV(s)
May 21, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
Presto Automation Announces Fiscal Third Quarter 2024 Financial Results
May 21, 2024 01:10 ET
|
Presto Automation Inc.
Presto Automation Announces Fiscal Third Quarter 2024 Financial Results
Litchfield Hills Research reiterates buy recommendation at $10.00 per share
May 21, 2024 01:10 ET
|
VIRTUALWARE 2007 SA
New York and Bilbao, Spain, 21 May - US equity research firm Litchfield Hills Research has just published a new analysis of Virtualware (ENXTPA: MLVIR), reiterating its Buy...
DNO to Hold Fixed Income Investor Meetings
May 21, 2024 01:00 ET
|
DNO ASA
Oslo, 21 May 2024 – DNO ASA, the Norwegian oil and gas operator, today announced it has engaged DNB Markets, part of DNB Bank ASA, and Pareto Securities AS as Global Coordinators and Joint Bookrunners...
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
May 21, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking...
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
May 21, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
May 21, 2024 01:00 ET
|
VALNEVA
Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief...